

# 中醫藥學院通訊

## SCM NEWSLETTER

2022年6月 | JUN 2022

學院抗疫 不遺餘力

SCM steps up efforts to fight COVID-19



**專題 FEATURE**

中藥創新研發中心拓展本港中藥研發路向

Centre for Chinese Herbal Medicine Drug Development sets course for greater advancement in the creation of novel Chinese medicine drugs in Hong Kong

專題 Features

學院抗疫 不遺餘力 <b>SCM steps up efforts to fight COVID-19</b>	03~08
--	-------

中藥創新研發中心拓展本港中藥研發路向 <b>Centre for Chinese Herbal Medicine Drug Development sets course for greater advancement in the creation of novel Chinese medicine drugs in Hong Kong</b>	09~12
---	-------

研究焦點 Research Focus

賈偉教授團隊揭示膽汁酸－微生物串擾 促進胃癌發展的新機制 <b>Team led by Professor Jia Wei unveils a novel mechanism by which bile acid-microbiome interaction promotes gastric carcinogenesis</b>	13~14
---	-------

賈偉教授團隊發現腸道菌與膽汁酸的交互 反應在調控節食後體重反彈中發揮重要作用 <b>Professor Jia Wei's team identifies the critical role of gut microbiota-bile acid crosstalk in mediating rebound weight gain after calorie restriction</b>	15~16
--	-------

王凱亮博士與卞兆祥教授領導的研究發現 新飽腹感調節機制及治療肥胖標靶 <b>Research led by Dr. Xavier Wong and Professor Bian Zhaoxiang identifies new regulatory mechanism of satiety and therapeutic target for obesity</b>	17~18
--	-------

臨床觀測 Clinical Observation

學院招募自閉兒童參與針灸治療臨床研究 <b>SCM recruits participants for clinical studies on acupuncture for children with autism</b>	19
---	----

學術及專業活動 Academic and Professional Activities	20~21
--	-------

學院動態 Highlights	22~29
-----------------	-------

學生・校友 Students・Alumni	30
-----------------------	----

新面孔 New Faces	31
---------------	----

聯絡資料 Contact Us	32
-----------------	----

# 學院抗疫 不遺餘力

SCM steps up efforts to fight COVID-19



學院中醫師在「浸大中醫抗疫遠程醫療中心」為病人進行網上診症。

Chinese medicine practitioners of SCM conduct online consultations with patients at the HKBU Chinese Medicine Telemedicine Centre Against COVID-19.

## 第五波新冠病毒疫情為香港帶來嚴峻挑戰，年初確診個案數字居高不下，導致醫療系統不勝負荷。有見及此，香港浸會大學中醫藥學院於2月中旬推出「2019冠狀病毒感染人士免費網上診症服務」，迅速回應社區對醫療援助的殷切需求。學院不僅得到大學鼎力支持，更獲騰訊公益慈善基金會慷慨捐出港幣1,000萬元，讓學院廣受歡迎的服務能夠惠及更多市民。

學院醫療團隊視照顧長者福祉為首要任務，尤其是患有慢性疾病的長者。事實上，高齡人士是受疫情影響最深的一群，為保障他們的健康，學院為多家安老院舍安排遙距醫療服務，並進駐啟德暫託中心向長者提供即場醫療護理。

The fifth wave of the COVID-19 pandemic has dealt a heavy blow to Hong Kong and saw the healthcare system overwhelmed by a spike in cases earlier this year. The School of Chinese Medicine (SCM) at Hong Kong Baptist University (HKBU) responded swiftly to the growing demand for medical help in the community by launching the "Free Online Consultation Service for COVID-19 Patients" in mid-February. With strong support from the University and the generous donation of HK\$10 million from the Tencent Charity Foundation, the School was able to deliver the highly sought-after service to more people.

The well-being of elders, especially those with chronic health conditions, remains a prime concern for SCM's medical team. To safeguard the health of this demographic which has been hardest hit by the pandemic, SCM has been providing remote medical services to elderly care homes and offering on-site medical care for resident elders at the Kai Tak Holding Centre.





學院為「2019冠狀病毒感染人士免費網上診症服務」計劃的參加者提供配藥及速遞服務，費用全免。

SCM provides free medicine dispensing and delivery services to participants of the "Free Online Consultation Service for COVID-19 Patients".

### 學院聯同浸大其他部門 全面看顧疫症患者

在 Omicron 變異病毒株肆虐的高峰期，香港每天出現數以萬計的新病例，公共醫療體系承受龐大壓力，大量市民急需求診就醫。

不少抵抗力弱的人士聚集在高感染風險的環境（如安老院舍），控制疫症爆發的工作亦因此變得格外艱鉅。確診者以至他們的照顧者和密切接觸者，除了急需防治疾病的支援，也需要專業人士協助緩解情緒壓力。

浸大校長衛炳江教授表示：「浸大一直致力推進中醫藥研究前沿，而中醫藥防治新冠病毒的成效亦已獲得臨床驗證，故此浸大因應疫情發展，本著關愛精神，迅速安排中醫藥學院組織一支醫療團隊，參與新冠病毒的防治工作，希望盡力幫助有急切需要的病人，舒緩公共醫療體系的壓力。同時，我們的社會工作系為安老院舍的長者和員工提供情緒支援及輔導，照顧他們的心理健康；多個大學部門則提供相關的行政支援，攜手應對疫情帶來的挑戰。」

### SCM joins forces with other HKBU units to provide comprehensive care for COVID-19 patients

The public health system was overstretched when the city was faced with tens of thousands of new infections daily at the peak of the Omicron surge, resulting in a large number of people seeking urgent medical treatment.

In a densely populated environment full of many vulnerable people at high risk of infection (such as those in elderly homes), managing the disease outbreak was particularly challenging. Apart from urgent support for disease prevention and treatment, patients – as well as their carers and close contacts – were in need of professional help to overcome their emotional distress.

Professor Alexander Wai, President and Vice-Chancellor of HKBU, said: "HKBU is devoted to advancing the frontier of Chinese medicine research, and the efficacy of Chinese medicine for the prevention and treatment of COVID-19 has been proven clinically. In view of the pandemic's development and in line with our caring spirit, the University has promptly assembled a team of medical professionals from SCM to participate in the fight against the virus, with the hope of helping patients with urgent needs and alleviating the pressure on the public healthcare system. At the same time, our Department of Social Work is also offering an emotional support and counselling service in elderly homes to take care of the mental health of patients and staff. A number of university departments are also providing administrative support, with the aim of joining hands to tackle the COVID-19 challenge."

## 騰訊慷慨解囊 助學院贈醫施藥

學院臨床部於2月中旬推出「2019冠狀病毒感染人士免費網上診症服務」，當時正值單日確診個案飆升的時期。此項服務專為無須入院但須在社區接受隔離的輕症患者而設。臨床部中醫師透過 WhatsApp 視像通話為受感染人士診症，再根據其臨床病徵和體質處方，並提供配藥服務。相關診金、藥費和速遞費用全免。

有見公眾對服務反應踴躍，大學旋即調配資源，設立「浸大中醫抗疫遠程醫療中心」，集中處理預約、應診和送藥安排，並建立專屬網上平台，方便公眾登記使用服務。

騰訊亦迅速透過旗下的騰訊公益慈善基金會向大學捐助港幣1,000萬元，支持學院的抗疫行動，為更多有需要的病人和密切接觸者適時提供免費服務。截至5月6日，這項服務惠澤超過40,000人。

### SCM offers free consultations and medication with support from Tencent Charity Foundation

When daily COVID-19 cases began to soar in mid-February, the Clinical Division (CLNC) of SCM launched the "Free Online Consultation Service for COVID-19 Patients". It targeted patients under quarantine in the community with no critical symptoms who did not require hospitalisation. Chinese medicine practitioners of CLNC would conduct consultations with patients through WhatsApp video-conferencing, prescribe medicine for them according to their clinical symptoms and body constitutions, and provide a medicine dispensing service. The consultation, medicine and delivery were free of charge.

In consideration of the overwhelming public demand for the service, the University wasted no time in gathering together the resources needed to set up the HKBU Chinese Medicine Telemedicine Centre Against COVID-19 as an integrated hub to handle appointments, consultations and drug delivery matters. A designated online platform was also constructed to facilitate public registration for the service.

Tencent was quick to show support for SCM's anti-epidemic efforts by pledging to donate HK\$10 million to the University through the Tencent Charity Foundation. The donation has enabled the School to offer free and timely service to more patients and close contacts in need. As of 6 May, more than 40,000 people have used this service.

學院職員與學生接聽公眾有關新冠網上診症服務的來電。

Staff and students of SCM receive incoming calls from the public on the COVID-19 online consultation service.



### 學院為安老院舍及啟德暫託中心長者提供特別護理

鑑於疫情在安老院舍爆發情況嚴重，學院與香港老年學會合作推出專門計劃，為獲認證院舍的長者及員工遙距診症和送藥，有關服務亦適用於由醫院管理局轉介的安老院舍，至今已有約100所安老院舍受惠。學院同時為聖雅各福群會的員工提供該項服務，以助他們持續照料近5,200名居家長者。

此外，學院派出一支由11名中醫師組成的醫療隊伍，照顧入住啟德暫託中心的長者。中心由社會福利署管理，負責接收由醫院管理局轄下醫院出院的輕症長者病人，以及經評估後須接受隔離的院舍長者。中心設有1,200張病床，浸大受委託營運當中的393張。學院團隊在食物及衛生局資助下，為入住長者提供中醫藥治療服務，並與駐場西醫、護士和藥劑師，以及來自內地的健康護理員共同照顧長者其他方面的醫療和藥物需要。學院亦為中心內由基督教靈實協會負責營運的393張病床，提供處方中藥服務，為入住病人提供另一治療方案。

### SCM provides special care for elderly residents of care homes and Kai Tak Holding Centre

In view of the serious nature of the outbreaks in elderly homes, SCM cooperated with the Hong Kong Association of Gerontology on a special scheme which offered remote consultations and medicine delivery to the residents and staff members of accredited elderly homes. The service has also been made available to elderly homes referred by the Hospital Authority. Around 100 elderly homes in total have benefited from the scheme. The service was also extended to staff members of St. James' Settlement to help them maintain continuous services to around 5,200 home-based elders.

Furthermore, a team comprising 11 Chinese medicine practitioners was dispatched by the School to tend to the elderly residing in the Kai Tak Holding Centre managed by the Social Welfare Department. The Centre was designated for the admission of elderly COVID-19 patients with mild symptoms who were discharged from the hospitals of the Hospital Authority, and residents of elderly care homes who needed to be quarantined after assessment. HKBU was appointed to operate 393 out of the 1,200 beds in the Centre. With the sponsorship of the Food and Health Bureau, the SCM team provided Chinese medicine-based treatment services to the resident elderly and joined hands with the on-site doctors, nurses and pharmacists, as well as care workers from the Mainland, to take care of the other medical and pharmaceutical needs of the elders. In addition, SCM provided a Chinese medicine prescription service for the Centre's 393 beds operated by the Haven of Hope Christian service, offering patients an alternative treatment plan.





## 學院抗疫 持久作戰

臨床部主任卞兆祥教授表示，是次學院參與新冠病毒診治，不僅為師生帶來寶貴經驗，更有助強化中醫藥在本港醫療體系的角色。

他指出：「學院根據臨床治療觀察，結合業界經驗，並參考內地的新冠病毒診療方案，制定《香港新型冠狀病毒感染中醫診療方案》，涵蓋新冠病毒的中醫預防，以及輕度及中度感染患者的治療和康復方案。我們希望透過編撰這套方案，為浸大的新冠病毒臨床診療提供規範，並供業界參考運用，長遠而言為採用中醫藥防治新發性疫病作出貢獻。」

院長呂愛平教授說：「年初香港新冠病例呈幾何級數增長，各界均措手不及，但這亦是政府加強利用中醫藥治療新冠患者的好時機。在最新一波疫情中，大眾對學院醫療服務的需求有增無減，足證中醫藥獲社會廣泛視為治療新冠症狀的可行方式。我們相信讓學生親身體驗中醫藥如何協助解決公共衛生危機，並了解社會對中醫藥的接受程度，實屬重要的一課，因此我們招募學生在『浸大中醫抗疫遠程醫療中心』擔任助手，並安排部分學生在啟德暫託中心實習。接下來，如何協助市民應對長期新冠症狀是值得大家深思的課題。」

浸大派出由學院中醫師組成的醫療隊伍照顧啟德暫託中心的長者。  
HKBU deploys a team of Chinese medicine practitioners from SCM to provide medical services to elderly at the Kai Tak Holding Centre.





中醫學本科及碩士課程學生在啟德暫託中心進行臨床實習。

Students of the Bachelor of Chinese Medicine and Bachelor of Science (Hons) in Biomedical Science and the Master of Chinese Medicine programmes conduct practicum in the Kai Tak Holding Centre.

### SCM in the fight for the long haul

Professor Bian Zhaoxiang, Director of CLNC, said that the participation of SCM in the treatment of COVID-19 has provided staff and students with a valuable experience and strengthened the role of Chinese medicine in Hong Kong's healthcare system.

He said: "By combining our clinical treatment observations and the experience of the Chinese medicine sector, and with reference to the Mainland's COVID-19 treatment protocol, SCM has compiled the "COVID-19 Chinese Medicine Diagnosis and Treatment Protocols for Hong Kong". It covers the Chinese medicine approach to the prevention of COVID-19, as well as the treatment and rehabilitation of patients with mild to moderate cases of the disease. We hope that the compilation of this protocol can standardise HKBU's clinical treatment for COVID-19, provide an operational reference for the Chinese medicine sector, and contribute to the adoption of Chinese medicine in terms of the prevention and treatment of emerging infectious diseases in the long run."

Professor Lyu Aiping, Dean of Chinese Medicine, said: "The exponential increase in COVID-19 cases early this year caught the city off guard but it also set the scene for the government to reinforce the use of Chinese medicine in treating COVID-19 patients. The keen demand for SCM's medical service during the latest wave of the pandemic goes to show that Chinese medicine is widely accepted by the community as a viable treatment for COVID-19 symptoms. We found it important for our students to experience at first hand how Chinese medicine can help in a public health crisis and how the community receives it, so we engaged our students as helpers at the HKBU Chinese Medicine Telemedicine Centre Against COVID-19 and arranged for some to conduct practicum in the Kai Tak Holding Centre. Something for us all to think about next will be what we can bring to the table to help people manage long COVID symptoms."



# 中藥創新研發中心 拓展本港中藥研發路向

Centre for Chinese Herbal Medicine Drug Development  
sets course for greater advancement in the creation of  
novel Chinese medicine drugs in Hong Kong

為中心揭幕的包括（左至右）院長呂愛平教授、副校長（研究及拓展）郭毅可教授、校長衛炳江教授、暫任常務副校長黃偉國教授，以及臨床部主任兼中藥創新研發中心總裁卞兆祥教授。

At the Centre's officiating ceremony (left to right): Professor Lyu Aiping, Dean of Chinese Medicine; Professor Guo Yike, Vice-President (Research and Development); Professor Alexander Wai, President and Vice-Chancellor; Professor Rick Wong, Interim Provost; and Professor Bian Zhaoxiang, Director of CLNC and CDD.



浸大中醫藥學院科研實力雄厚，在轉化研究和創新藥物發現方面成果卓著，為進一步推動創新中藥的研發，引領中藥開發逐步走向標準化和國際化，浸大特別成立「中藥創新研發中心」。

## 本地大學首間綜合性中藥研發中心

中心位於香港科學園，是唯一一所獲香港特別行政區政府創新科技署「InnoHK 創新香港研發平台」資助，並由本地大學建立和運作的綜合性中藥藥物研發中心。中心與世界級夥伴攜手開展高質量的臨床前和臨床中藥研究，並將結果轉化為符合國際標準和市場需求的醫藥產品。中心的合作夥伴包括芝加哥大學唐氏草藥研究中心、澳門大學中藥質量研究國家重點實驗室，以及浸大環境與生物分析國家重點實驗室。

中心於去年12月22日正式揭幕，由浸大校長衛炳江教授、暫任常務副校長黃偉國教授、副校長（研究及拓展）郭毅可教授、院長呂愛平教授，以及臨床部主任兼中心總裁卞兆祥教授主禮。



中藥創新研發中心總裁卞兆祥教授（右）及高級科學主任林成源博士（左）表示，中心能一站式處理整個中藥研發過程。

Professor Bian Zhaoxiang, Director (right), and Dr. Lin Chengyuan, Senior Scientific Officer of CDD (left), said the Centre can handle the entire research and development process for Chinese medicine drugs in a one-stop manner.

### 提升本港中藥產品競爭力

針對中藥的整個研發過程，中心設有六大研究平台，分別為「臨床數據科學研究組」、「腸道菌群與代謝研究組」、「免疫和腸道炎症研究組」、「中藥藥學研究組」、「人工智慧驅動藥物開發研究組」和「藥品註冊申請組」。各個研究平台既可互相協作，綜合處理創新中藥的整個研發過程，亦可獨立運作，為個別中藥配方進行相關的臨床前或臨床研究。

衛校長表示：「浸大在中草藥藥物研發方面饒富經驗，中心亦擁有完善設施，讓我們的中醫藥專家能夠一站式處理整個中藥臨床前研發過程，當中包括中藥成分分析、藥理分析、藥效和安全性評估。在2025年，由浸大負責營運的首間香港中醫醫院將可進行臨床實驗，以助完成藥物開發過程。浸大具備完整的中藥基礎科學研究、臨床前研究及臨床測試能力，研發有效中醫藥的工作將會更上一層樓，並讓本港的中藥產品在地區以至國際層面更具競爭力。」

Building upon the research strength of SCM in translational medicine and innovative drug discovery, the University has established the Centre for Chinese Herbal Medicine Drug Development (CDD) with a vision to become a driving force for the advancement, standardisation and internationalisation of the development of Chinese medicine based-drugs.

### First integrated Chinese medicine drug research centre operated by a local university

Located within the Hong Kong Science Park, CDD is the only integrated Chinese medicine drug research and development centre supported by the InnoHK initiative under the Innovation and Technology Commission of the HKSAR Government and the first of its kind to be established and operated by a local university. Along with its global partners, CDD undertakes to conduct quality preclinical and clinical Chinese medicine research and translate the results into pharmaceutical products that meet international standards and market needs. Its collaborators include the Tang Center for Herbal Medicine Research at The University of Chicago, the State Key Laboratory of Quality Research in Chinese Medicine at the University of Macau, and the State Key Laboratory of Environmental and Biological Analysis at HKBU.

The Centre was officially opened on 22 December last year at a ceremony officiated by Professor Alexander Wai, President and Vice-Chancellor of HKBU; Professor Rick Wong, Interim Provost of HKBU; Professor Guo Yike, Vice-President (Research and Development) of HKBU; Professor Lyu Aiping, Dean of Chinese Medicine; and Professor Bian Zhaoxiang, Director of CLNC, who is also the Director of CDD.

## 開發治療便秘及結腸炎新藥

中心的藥物研發策略，是以獲得研究驗證的中藥配方為基礎，按照國家藥品監督管理局、香港中醫藥委員會及美國食品藥品監督管理局植物藥研發的標準，並且針對市場所需，開發以中藥為本的新藥物。其中，治療慢性便秘和潰瘍性結腸炎的藥物是中心的研究重點。

慢性便秘是常見的腸胃疾病，資料顯示全球約14%的人口受這個疾病困擾。現時慢性便秘的一線治療藥物對部分患者而言，效果未如理想。為回應市場對新藥物的需求，中心著手研究傳統中藥複方，發現其潛在療效勝於現時的一線治療藥物。中心的研究團隊以此為基礎，依據美國植物藥開發的要求，嘗試研發以草藥治療便秘的新藥，並會對其作用機制進行深入廣泛的研究。

潰瘍性結腸炎是最普遍的炎症性腸病，可引致整個結腸組織損傷，並在隨後出現炎症反應。大多數患者會處於炎症復發和病情緩解的交替狀態之中，導致生活質素嚴重下降。由於潰瘍性結腸炎至今未有根治方案，故中心正研究一種在臨床治療中證實可有效緩解相關徵狀的中藥複方製劑，並結合中醫、生藥學、藥理學和生物資訊學背景的知識，將該中藥複方製劑開發成為治療潰瘍性結腸炎的藥物，同時深入探討其治療作用機理。

## Enhancing the competitiveness of Hong Kong's Chinese medicine drugs

In line with the entire research and development process for Chinese medicine drugs, the Centre has set up six research platforms, namely the Clinical Data Science Group, the Gut Microbiota and Metabolism Group, the Immunology and Gut Inflammation Group, the Chinese Medicine Pharmacognosy Group, the AI-driven Drug Discovery Group and the Drug Application Group. The research platforms can work together to handle the entire research and development process for new Chinese medicine drugs, or they can work independently to conduct related preclinical or clinical studies for a specific Chinese medicine formula.

Professor Alexander Wai said: "With HKBU's extensive experience in Chinese herbal medicine drug development, and the comprehensive range of facilities available at CDD, our Chinese medicine experts can perform the entire Chinese medicine preclinical development process in a one-stop manner, including Chinese medicine component analysis, pharmacological studies, as well as efficacy and safety assessments. In 2025, Hong Kong's first Chinese Medicine Hospital to be operated by HKBU will help complete the drug development process with clinical trials. With a full range of basic science research, preclinical study and clinical trial capabilities for Chinese medicine, HKBU will help take the research and development of effective Chinese medicine drugs to another level of excellence, and improve the competitiveness of Hong Kong's Chinese medicine pharmaceutical products regionally and even internationally."

## Developing new drugs for constipation and inflammatory bowel disease

The Centre's strategy is to use Chinese medicine formulas supported by research evidence as the foundation for new Chinese medicine-based drugs. This will be done in line with the requirements for botanical drugs as stipulated by the National Medicinal Products Administration (NMPA) of China, the Chinese Medicine Council of Hong Kong, and the Food and Drug Administration (FDA) of the US, and in response to market demands. The treatment of chronic constipation and inflammatory bowel disease is the research focus of the Centre.

Chronic constipation is a common gastrointestinal disorder that affects about 14% of the world's population according to sources. The efficacy of existing first-line chronic constipation drugs is unsatisfactory for some patients. To address the need of the market for a new drug, CDD carried out research on a traditional Chinese medicine formula and found that its potential treatment effects are better than that of the existing first-line drugs. Based on this finding, the Centre's research team has attempted to develop a herbal drug as a novel treatment for constipation in compliance with the botanical drug development requirements in the US. The team will also conduct in-depth analysis on the treatment mechanism of the new drug.



「超高效液相色譜儀附四級杆—飛行時間儀」可用於識別中藥成分和代謝組學分析。

The ultra high-performance liquid chromatography with Quadrupole – Time of Flight System is a valuable tool for traditional Chinese medicine components and metabolomic profiling.



### 促進中藥標準化和國際化

卞教授指出，中心的藥物研發策略體現了「傳統智慧、創新藥物」的宗旨。

他表示：「中心的中藥研發工作，使用廣受市場採納的國際標準，把傳統中藥複方結合先進醫學科技和知識，再轉化為創新藥物，從而促進中藥的標準化和國際化。」

卞教授續指：「中心匯聚最先進的儀器、技術和優秀人才，此綜合平台能夠處理整個中藥研發過程。我相信中心的運作模式，能夠為加快香港在創新中藥開發方面的發展，提供寶貴的參考。」



長遠而言，中心將支持以全球市場為導向的新藥研發初創企業，並整合浸大在中醫藥教學、研究和臨床服務的優勢，培育本地中醫藥研究人才。

中心的「全自動多通道器官浴系統」，用作測試離體器官用藥後的功能。

The Centre's fully automatic and compact multi chamber tissue bath system is used to measure the function of isolated organs or tissues after administration of drugs.

Ulcerative colitis is the most common inflammatory bowel disease that causes tissue damage and subsequent inflammatory response in the colon. Most patients suffer from alternating states of clinical relapse and remission which leads to severe deterioration of their quality of life. As there is no curative treatment for the disease, CDD is researching into a Chinese herbal formula that has been clinically applied and proven to be effective in relieving symptoms related to ulcerative colitis. The research team has drawn on its professional knowledge of traditional Chinese medicine, pharmacognosy, pharmacology and bioinformatics to develop the Chinese herbal formula into a novel ulcerative colitis drug and understand its treatment mechanism.

### Promoting the standardisation and internationalisation of Chinese medicine

Professor Bian pointed out that the Centre's drug development strategy embodies its motto of "Traditional Wisdom, Innovative Drugs". He said: "The Centre's Chinese medicine drug development process adopts international standards that have been widely recognised by the market. It integrates advanced medical technologies and knowledge with traditional Chinese medicine formulas, and it turns them into innovative drugs, thereby promoting the standardisation and internationalisation of Chinese medicine."

"The Centre is an integrated platform that houses the most advanced medical equipment and technologies as well as outstanding talent, and it can handle the entire research and development process for Chinese medicine drugs. I believe the Centre's operating model can provide a valuable reference on how to accelerate Hong Kong's growth in the area of novel Chinese medicine drug development," added Professor Bian.

In the long run, CDD will support the incubation of new drug development start-ups that target the global market, and unite HKBU's strengths in Chinese medicine education, research and clinical service to nurture local talent for Chinese medicine research.

# 賈偉教授團隊揭示膽汁酸－微生物串擾促進胃癌發展的新機制

Team led by Professor Jia Wei unveils a novel mechanism by which bile acid-microbiome interaction promotes gastric carcinogenesis

賈教授團隊發現源自丹參的天然化合物隱丹參酮能有效減緩膽汁反流誘發的胃癌前病變。

Professor Jia's team discovered that Cryptotanshinone, a natural compound extracted from Danshen, can effectively attenuate gastric carcinogenesis induced by bile reflux.



由張安德中醫藥教授兼副院長（國際合作）賈偉教授領導的研究成功確定膽汁酸－微生物串擾促進胃癌發展的機制。是項研究揭示了膽汁反流與產脂多糖（LPS）的微生物促使胃癌病變的有害作用，同時證實了隱丹參酮能有效抑制膽汁反流引起的胃癌病變，為與膽汁反流性胃炎相關的胃癌帶來嶄新的預防和治療策略。有關研究更獲國際科學期刊《Advanced Science》選為封面文章。

## 膽汁反流性胃炎與胃癌癌前病變密切相關

膽汁反流可誘發胃癌癌前病變，但具體機制尚待確定。研究團隊通過超高效液相色譜串聯三重四級杆質譜分析，比較對照組、膽汁反流性胃炎患者和胃癌患者的胃液膽汁酸成分，結果顯示兩類

A study led by Professor Jia Wei, Cheung On Tak Endowed Professor in Chinese Medicine and Associate Dean (International Collaboration) of Chinese Medicine, has proved the mechanistic role of bile acid-microbiome interaction in gastric carcinogenesis. The study revealed the deleterious role of refluxed bile acids and lipopolysaccharide (LPS)-producing bacteria in promoting gastric carcinogenesis and showed the potential therapeutic effect of Cryptotanshinone in attenuating gastric carcinogenesis induced by bile reflux. Results from the study provided a novel strategy for the prevention and treatment of gastric cancer (GC) associated with bile reflux gastritis (BRG). The related work has been published as a cover paper in the international scientific journal *Advanced Science*.

## Bile reflux gastritis is closely associated with precancerous gastric lesions

Bile reflux promotes the development of precancerous gastric lesions but the exact mechanism remains elusive. Using an ultra-performance liquid chromatography coupled with a triple quadrupole mass spectrometry (UPLC/TQMS) based targeted

患者的整體膽汁酸水平顯著升高，其中結合型膽汁酸包含的甘膽酸（GCA）、甘氨鵝去氧膽酸（GCDCA）、甘氨去氧膽酸（GDCA）、甘氨去氧膽酸（GUDCA）、牛磺膽酸（TCA）、牛磺鵝去氧膽酸（TCDCA）、牛磺去氧膽酸（TDCA）和牛磺熊去氧膽酸（TUDCA）升幅尤為明顯。研究人員進一步發現膽汁反流性胃炎和胃癌患者的 TDCA 水平與胃液 pH 值呈特異性的正相關。

### 結合型膽汁酸增加胃腔內分泌 LPS 的微生物豐度，並促進胃癌發展

過去研究表明膽汁酸反流與胃部慢性炎症密切相關。研究團隊先評估膽汁反流性胃炎和胃癌患者的胃液促炎性細胞因子水平，發現兩類患者的胃液促炎性細胞因子以及生產 LPS 的微生物水平均顯著升高。隨後，研究人員通過細胞實驗和動物實驗探究膽汁反流如何促成胃癌前病變。研究團隊在細胞實驗中發現 TDCA 和 LPS 會加速胃上皮細胞的增殖，而在動物實驗中則發現 TDCA 和 LPS 均能促進小鼠的胃炎。兩項實驗的結果進一步揭示 TDCA 和 LPS 通過啟動 IL-6/JAK1/STAT3 通路促進胃部炎症以及癌變。

### 取自中藥丹參的隱丹參酮能夠改善膽汁反流導致的胃癌癌前病變

隱丹參酮是提取自中藥丹參的生物活性化合物，屬天然的 STAT3 抑制劑。研究團隊為膽汁反流模型小鼠注入隱丹參酮，結果發現隱丹參酮能明顯減緩由膽汁反流造成的胃癌前病變。

賈偉教授的研究團隊不僅揭示了膽汁反流促進胃部癌變的重要機制，更為治療膽汁反流性胃炎以及預防與其相關的胃癌找到有效的藥物。同時，研究團隊建立了更貼近膽汁反流性胃炎臨床表型的小鼠模型，為研究其他相關代謝通路在膽汁反流性胃炎中的作用提供了有效的實驗手段。

metabolomics approach, the research team measured the bile acid profiles of the gastric juice samples among control, BRG and GC groups. The results showed that the total bile acids, especially conjugated bile acids, including glycocholic acid (GCA), glycochenodeoxycholic acid (GCDCA), glycodeoxycholic acid (GDCA), glyoursodeoxycholic acid (GUDCA), taurocholic acid (TCA), taurochenodeoxycholic acid (TCDCA), taurodeoxycholic acid (TDCA), and taoursodeoxycholic acid (TUDCA), were significantly elevated in patients with BRG and GC. They further identified a strong positive correlation between the TDCA levels and pH value of human gastric juice in both BRG and GC patients.

### Conjugated bile acids increase the abundance of LPS-secreting microbiota in the gastric compartment and promote gastric carcinogenesis

Previous studies showed that bile acids refluxing into the stomach were closely related to chronic inflammation. The research team first evaluated the levels of pro-inflammation cytokines in the gastric juice of BRG and GC patients and found that the concentrations of pro-inflammatory cytokine and LPS-producing bacteria were significantly increased in BRG and GC patients. They then performed both *in vitro* and *in vivo* experiments to decipher the mechanism through which bile reflux promoted precancerous gastric lesions. Their *in vitro* study found that TDCA and LPS promoted gastric epithelial cell proliferation while their *in vivo* study discovered that both TDCA and LPS induced gastric inflammation in mice. The findings of their studies further suggested that TDCA and LPS stimulated gastric inflammation and gastric carcinogenesis by activating the IL-6/JAK1/STAT3 signalling pathway.

### Cryptotanshinone derived from *Salvia miltiorrhiza* attenuates bile reflux-induced gastric precancerous lesions

Cryptotanshinone is a bioactive natural product extracted from the roots of the Chinese medicinal plant *Salvia miltiorrhiza* that specifically inhibits STAT3 signalling. By administering Cryptotanshinone to the bile reflux mouse model, the team demonstrated that Cryptotanshinone could significantly attenuate bile reflux-induced gastric precancerous lesions.

The study led by Professor Jia has not only uncovered the underlying mechanism that explains how bile reflux promotes gastric carcinogenesis, but also identified an effective therapeutic and preventive solution to clinical intervention in BRG and BRG associated GC. The mouse model established by the team to mimic the clinical phenotypes of BRG can also be used for investigating the role of other metabolic signalling pathways in BRG.



# 賈偉教授團隊發現 腸道菌與膽汁酸的交互反應 在調控節食後體重反彈中發揮重要作用

Professor Jia Wei's team identifies  
the critical role of gut microbiota-bile acid crosstalk in  
mediating rebound weight gain after calorie restriction


賈教授領導的研究發現，限制卡路里攝取會改變小鼠的腸道微生物生態和新陳代謝，從而導致能量消耗減弱和體重反彈。

Research led by Professor Jia found that calorie restriction altered microbiota and reprogramed metabolism in mice, resulting in reduced energy and weight regain.

賈偉教授領導的另一項研究首次證實腸道菌與膽汁酸的交互反應在調控節食後體重反彈中的重要作用。該項研究揭示節食會顯著降低腸道有益菌青春雙歧桿菌和非12 $\alpha$ -羥基化膽汁酸的比例，導致機體能量代謝受損，從而令體重反彈，而補充青春雙歧桿菌或熊去氧膽酸（非12 $\alpha$ -羥基化膽汁酸的一種）則能有效改善節食後的體重反彈問題。相關研究成果近日刊登於國際科學期刊《Nature Communications》。

## 卡路里限制引致能量消耗減弱

研究團隊設計出斷食－復食小鼠模型和卡路里限制－復食小鼠模型，用以探究飲食干預對體重帶來的變化。通過分析兩個小鼠模型的代謝表型，團隊發現復食後小鼠體重顯著上漲，其糖耐量和胰島素敏感性則有所下降。同時，卡路里限制組小鼠的



Another study led by Professor Jia Wei has revealed the critical role of the crosstalk between gut microbiota and bile acid in modulating rebound weight gain after calorie restriction (CR). The study found that CR decreased the content of probiotic *Parabacteroides distasonis* in gut microbiota and the proportion of non-12 $\alpha$ -hydroxylated bile acids (non-12 $\alpha$ OHBAs), leading to reduced energy expenditure and weight regain. It also demonstrated that supplementation with *Parabacteroides distasonis* or ursodeoxycholic acid (UDCA, a kind of non-12 $\alpha$ OHBAs) could attenuate post-CR weight regain. These research findings have recently been published in the international scientific journal *Nature Communications*.

## CR reduces energy expenditure

The research team adopted a fasting mouse model and CR mouse model to investigate how dietary intervention modulates weight regain. By analysing the metabolic phenotypes of the two mouse models, they

能量消耗較對照小鼠弱，並出現更嚴重的脂肪肝和脂肪細胞肥大。

### 卡路里限制飲食改變小鼠腸道菌群和膽汁酸組成

研究團隊通過宏基因組分析上述兩種小鼠模型的腸道菌群分布，發現卡路里限制大大提高厚壁菌門與擬桿菌門的比例，而這可能是介導體重反彈的關鍵因素。團隊進一步發現青春雙歧桿菌和非12 $\alpha$ - 羥基化膽汁酸，特別是熊去氧膽酸和石膽酸的比例，在熱量限制後顯著降低。通過腸道菌群與非12 $\alpha$ - 羥基化膽汁酸的廣義相關性分析，團隊證實青春雙歧桿菌與大多數非12 $\alpha$ - 羥基化膽汁酸水平具顯著相關性。

### 青春雙歧桿菌和熊去氧膽酸能有效預防節食後體重反彈

團隊進一步研究體重反彈的小鼠，結果顯示補充青春雙歧桿菌或熊去氧膽酸均能有效改善小鼠的復胖情況。機制方面，研究團隊證實非12 $\alpha$ - 羥基化膽汁酸介導棕色脂肪中 TGR5-UCP1 的關鍵性產熱通路，有助維持正常能量代謝和體重。

綜合以上資訊，是項研究揭示腸道菌與膽汁酸的相互反應在介導熱量限制飲食後體重反彈中的重要作用和機制，同時確定青春雙歧桿菌為有效的營養補充劑，可改善因節食減肥造成腸道菌群紊亂而引致的體重反彈，這為預防肥胖帶來嶄新的策略。

found that body weight was significantly increased accompanied with glucose intolerance and insulin resistance after transition from CR to normal diet. Meanwhile, CR mice showed lower energy expenditure as well as more severe hepatic steatosis and adipocyte hypertrophy compared with the control mice.

### CR remodels the gut microbial ecosystem and bile acid composition

The research team conducted a whole-genome shotgun metagenomic sequencing in the two above-mentioned mouse models and found that the ratio of Firmicutes to Bacteroidetes was increased significantly after CR, which could possibly be the key regulator for weight regain. They further discovered that the abundance of *Parabacteroides distasonis* and the proportion of non-12 $\alpha$ OHBA, especially lithocholic acid and UDCA, were significantly decreased in CR group. Using generalised correlation analysis for metabolome and microbiome (GRaMM), they found that *Parabacteroides distasonis* had a strong correlation with most non-12 $\alpha$ OHBA.

### Treatment with *Parabacteroides distasonis* or UDCA prevents weight regain after CR diet

Their further studies showed that supplementation with *Parabacteroides distasonis* or UDCA significantly ameliorated weight regain in mice with CR. Mechanically, the research team proved that non-12 $\alpha$ OHBA activated the TGR5-UCP1 signalling pathway in brown adipose tissue (BAT), maintaining the normal energy expenditure and weight control.


Taken together, this study has revealed the critical role and mechanism of gut microbiota-bile acid crosstalk in rebound weight gain after CR. Meanwhile, *Parabacteroides distasonis* has been identified as an effective nutritional supplement for combating weight regain resulted from CR-induced alterations in gut microbiome composition, making it a promising novel therapeutic agent for the prevention of obesity.

# 王凱亮博士與卞兆祥教授領導的研究 發現新飽腹感調節機制及治療肥胖標靶

Research led by Dr. Xavier Wong and Professor Bian Zhaoxiang identifies new regulatory mechanism of satiety and therapeutic target for obesity

王凱亮博士（左）與卞兆祥教授（右）識別了一種名為 MT1-MMP 的水解蛋白酶，為研發治療肥胖症的創新藥物提供一個極具潛力的標靶。

Dr. Xavier Wong (left) and Professor Bian Zhaoxiang (right), identified a proteolytic enzyme called MT1-MMP which could serve as a promising potential drug target for the management of obesity.



由教學科研部助理教授王凱亮博士聯同曾肇添中醫藥臨床研究教授兼臨床部主任卞兆祥教授領導的研究團隊，發現一種名為「膜1型基質金屬蛋白酶」（MT1-MMP）的蛋白水解酶，在飽腹感的調節機制中扮演重要角色，為研發治療肥胖症的創新藥物提供一個極具潛力的標靶。

研究結果已刊登於《Nature Metabolism》，並獲《Nature Reviews Endocrinology》、《Nature Metabolism》及《Science Signaling》重點介紹。

## 半數香港人口肥胖或過重

過重，尤其當達到肥胖程度時，會增加人們患上心血管疾病、糖尿病、癌症等致命疾病的風險。

A research team led by Dr. Wong Hoi-leong Xavier, Assistant Professor of the Teaching and Research Division (CMTR), and Professor Bian Zhaoxiang, Tsang Shiu Tim Endowed Professor in Chinese Medicine Clinical Studies and Director of CLNC, has found that a proteolytic enzyme called membrane-type 1 matrix metalloproteinase (MT1-MMP) plays an important role in the regulatory mechanism of satiety and it could serve as a promising potential drug target for the management of obesity.

The research findings were published in *Nature Metabolism*, and featured as a research highlight in *Nature Reviews Endocrinology*, *Nature Metabolism* and *Science Signaling*.

## Half of Hong Kong's population obese or overweight

Being overweight, especially to the extent of obesity, exposes people to a higher risk of life-threatening diseases such as cardiovascular diseases, diabetes, and cancer. According to the Population Health Survey conducted in 2014/15 by the



根據衛生署在2014/15年進行的人口健康調查，年齡介乎15至84歲的香港人當中，約30%屬於肥胖，另有20%過重。應對肥胖最有效的方法是減少進食，但肥胖的人往往因無法滿足食慾而未能好好控制食量。因此，要制定肥胖症的有效療法，首要是辨別出控制體重的關鍵因素，並研究相關因素如何調節飽腹感。

### 識別新的飽腹感調節因子

研究團隊通過給予小鼠富含脂肪（45%）的飲食，模擬人類的超重狀況，從而建立肥胖症的小鼠模型。研究顯示肥胖小鼠腦幹後區和孤束核的MT1-MMP活性有所增加，而這些腦區正好與食慾和體重調節有關。團隊進一步發現，MT1-MMP從大腦神經元表面剪斷名為GFRAL的飽足激素GDF15受體，阻止GDF15與其結合，因而窒礙GDF15向神經元發出飽足信號。這些資料說明肥胖小鼠大腦中MT1-MMP活性增加，可能是導致肥胖情況下體重持續上升的風險因素。

### MT1-MMP 作為肥胖的治療標靶

為了探索MT1-MMP作為治療肥胖症標靶的潛力，團隊採取基因和藥物干預來抑制體內MT1-MMP的活性，並發現在飽腹感神經元中靶向敲除MT1-MMP的轉基因小鼠模型對高脂肪飲食引起的肥胖症有抵抗力。同樣地，通過使用特異性中和抗體對MT1-MMP進行藥物干預，在各種肥胖小鼠模型（包括高脂飲食致肥的小鼠和自發性肥胖小鼠）中，不論食物攝入量、葡萄糖耐量或體重等代謝參數均得到明顯改善。

王博士說：「研究結果確立了MT1-MMP在調控飽腹感的角色，並初步顯示了這種蛋白水解酶是治療肥胖症的有效標靶。以藥物抑制MT1-MMP，是研發能有效治療肥胖症的藥物的可行策略。」

此研究項目由學院聯同香港大學、香港中文大學、德克薩斯大學休斯頓健康科學中心和赫爾辛基大學的科學家合力完成。

Department of Health, about 30% of people in Hong Kong aged 15 to 84 were obese, and another 20% were overweight. The most effective way to tackle obesity is to reduce food consumption. However, individuals with obesity, more often than not, struggle to maintain control over their food intake as a result of their insatiable appetite. Identifying the specific factor that controls body weight and investigating how it regulates the sense of satiety is crucial for the development of therapeutic strategies for obesity.

### Identification of new regulator of satiety signals

The team developed a mouse model of obesity by feeding the mice a diet rich in fats (45%) to mimic the overweight conditions in humans. Obese mice showed increased activity of MT1-MMP in the area postrema and nucleus of the solitary tract, brain regions involved in appetite and weight regulation. They further found that MT1-MMP snips GFRAL, the receptor for the satiety hormone GDF15, from the surface of brain neurons, preventing GDF15 from binding to GFRAL and in turn blocking the transmission of satiety signals from GDF15 to the neurons. These data suggest that increased MT1-MMP activity in the brain of obese mice can be a risk factor for sustained weight gain in the context of obesity.

### MT1-MMP as a therapeutic target for obesity

To explore the potential of targeting MT1-MMP to treat obesity, the team adopted genetic and pharmacological approaches to inhibiting the activity of MT1-MMP *in vivo*. They found that the transgenic mouse model with targeted depletion of MT1-MMP in satiety neurons was resistant to high fat diet-induced obesity. Likewise, pharmacological inhibition of MT1-MMP using a specific neutralising antibody yielded significant improvements in metabolic parameters including food intake, glucose tolerance and body weight of various obese mouse models, inclusive of mice with high fat diet-induced obesity as well as spontaneously obese mice.

Dr. Wong said: "The research findings have established the role played by MT1-MMP in regulating satiety, and they have provided preliminary indications that the proteolytic enzyme is a promising target for the treatment of obesity. Pharmacological inhibition of MT1-MMP could be a viable strategy for the development of effective pharmacotherapy for the treatment of obesity."

This research project is a collaborative effort by SCM and scientists from The University of Hong Kong, The Chinese University of Hong Kong, the University of Texas Health Science Center at Houston and the University of Helsinki.

# 學院招募自閉兒童 參與針灸治療 臨床研究

SCM recruits participants  
for clinical studies on acupuncture  
for children with autism



學院近日在方潤華基金及中醫藥發展基金支持下，開展兩項以針灸治療兒童自閉症譜系障礙 (ASD) 的臨床研究。

ASD 屬神經發育障礙，患者會在社交、溝通和行為彈性方面出現不同程度的困難和發展差異。醫學界至今對自閉症的病因及病理特點未有明確定論，當前亦無藥物可治癒自閉症。儘管如此，過去臨床研究結果顯示，自閉症患者如同時接受常規和針灸治療，不論年齡和本身病情輕重，其症狀皆可獲得改善。

學院展開的兩項研究旨在宣揚以針灸治療自閉症的功效。研究團隊會按國際標準進行患者評估並發表循證報告，冀能鼓勵更多醫學界人士和自閉症兒童的家長採用針灸作為自閉症的輔助療法，並促進跨專業的合作與相互轉介，從而提升整體療效。

為此，學院現正招募合資格的自閉症兒童接受 36 至 72 次的針灸療程。如年齡介乎 3 至 12 歲，無神經或精神缺陷或癲癇病史，且目前並無服用任何抗癲癇藥物的兒童皆可報名參與此計劃。治療和評估費用全免。參加者可在整個療程中繼續接受常規治療和訓練。

有意者可掃描二維碼下載申請表，並將填妥的表格交回任何一間浸大中醫診所。如有查詢，請致電 3411 7015。

With the support of the Fong's Family Foundation and the Chinese Medicine Development Fund, SCM has recently initiated two clinical studies on acupuncture treatment for children with autism spectrum disorder (ASD).

ASD is a neurodevelopmental disorder characterised by varying degrees of impairment in social interaction, communication and behavioural flexibility. The medical community has not reached a clear consensus on the etiology and pathological characteristics of autism, and there is currently no medical cure for autism. Nonetheless, results from previous clinical studies indicated that patients who received acupuncture therapy alongside conventional treatments for autism showed improvements in their symptoms, regardless of age and severity of the pre-existing conditions.

The two studies conducted by SCM aim to raise public awareness of the efficacy of acupuncture in treating autism. By conducting patient assessments that conform to international standards and releasing evidence-based reports, the research team hopes to encourage a wider adoption of acupuncture as a complementary therapy for autism among medical professionals and parents of autistic children as well as to promote inter-professional collaborative practice and referral to optimise overall treatment outcomes.

To this end, SCM is now recruiting qualified autistic children for a course of 36-72 acupuncture treatments. Those aged 3-12 with no history of neurological or psychiatric disorders or epilepsy and are currently not on any antiepileptic medication are invited to enroll in the treatment programme. All treatments and assessments are free of charge. Participants can continue with their regular treatment and training during the entire course of the programme.

Interested parties may scan the QR code to download the application form, and return the completed form to any of the HKBU Chinese medicine clinics. For enquiries, please call 3411 7015.



## 榮譽教授探討傳統及現代中醫藥

Honorary professors explore traditional and contemporary Chinese medicine



SCM held the Eighth Honorary Professorship Seminar on 10 November 2021. It featured eight live-streamed lectures on topics including personalised cancer medicines, natural products in Chinese medicines, quality control of herbal medicines, computational acupuncture, and the culture and theories of traditional Chinese medicine. Around 400 people including local Chinese medicine practitioners as well as teachers and students of the School joined the Seminar.

The Seminar's distinguished speakers included Professor Ding Jian, Academician of the Chinese Academy of Engineering, who was conferred later that month the degree of Doctor of Science, *honoris causa*, by the University; Professor Sun Handong, Academician of the Chinese

學院於去年 11 月 10 日舉辦第八屆榮譽教授研討會，八場線上直播講座的主題涵蓋個性化腫瘤藥物、中藥天然產物、中藥品質管制、計算針灸學，以及中醫藥文化和理論，吸引近 400 名本地中醫師和學院師生參加。

與會講者包括在同月下旬獲大學頒授榮譽理學博士學位的中國工程院院士丁健教授、中國科學院院士孫漢董教授、福建中醫藥大學校長李燦東教授、中國中醫科學院中藥研究所所長陳士林教授、台灣中國醫藥大學中醫學院教授張永勳教授、黑龍江中醫藥大學副校長王喜軍教授、天津中醫藥大學中醫學院院長郭義教授，以及河南中醫藥大學基礎醫學院醫古文與中醫文獻學教研室教授許敬生教授。他們與另外七位著名學者獲學院頒授榮譽教授名銜，任期至 2023 年。

院長呂愛平教授致辭時表示，研討會因疫情而延期兩年，他很高興最終能邀得多位榮譽教授分享研究專長、臨床經驗和醫學知識，讓學術界和業界人士大開眼界，獲益匪淺。他表示學院會與各榮譽教授保持緊密聯繫，開拓更多合作機會，攜手進行跨學科研究工作。/


Academy of Sciences; Professor Li Candong, President of the Fujian University of Traditional Chinese Medicine; Professor Chen Shilin, Director of the Institute of Chinese Materia Medica at the China Academy of Chinese Medical Sciences; Professor Chang Yuan-shiun, Professor of the College of Chinese Medicine at the China Medical University in Taiwan; Professor Wang Xijun, Vice President of the Heilongjiang University of Chinese Medicine; Professor Guo Yi, Dean of the School of Traditional Chinese Medicine at the Tianjin University of Traditional Chinese Medicine; and Professor Xu Jingsheng from the Henan University of Chinese Medicine. Along with seven other notable academics, they were appointed honorary professors by SCM until 2023.

In his address, Professor Lyu Aiping, Dean of Chinese Medicine, said that the organisation of the Seminar was deferred for two years because of the pandemic. He added that he was delighted that the School was finally able to present academia and the professional sector with an eye-opening opportunity to benefit and draw inspiration from the honorary professors' wealth of research expertise, clinical experience and medical knowledge. He said SCM will capitalise on its strong ties with the honorary professors to develop and engage in more collaborative and interdisciplinary research projects. /



## 張世平博士介紹舌診及抗疫飲食

Dr. Zhang Shi-ping introduces tongue diagnosis and diet against COVID-19



中醫認為 2019 冠狀病毒病屬於「寒濕疫」，而體內濕氣積聚的一大徵狀正是舌苔厚膩。為加深公眾對中醫濕氣和舌診概念的認識，並向市民提供祛濕飲食良方，教學科研部副教授張世平博士在 4 月 7 日舉辦網上講座，並邀得美食專欄作家葉澍堃先生擔任嘉賓主持。

張博士在講座上介紹其團隊研發的標準拍攝流程，示範以智能手機拍攝高清舌頭圖像，並講解其團隊開發的手機應用程式 (i-heals.com) 如何利用人工智能技術分析舌頭圖像。

此外，張博士在活動上展示新冠患者的舌頭圖像，說明由病發到康復期間的舌象變化。他又介紹多款湯方，幫助不同體質和染疫階段的人士有效祛濕。是次網上講座吸引近 200 名市民收看直播，而 YouTube 頻道亦在短短數日內累積達 1,000 觀看人次。

此前，張博士為中醫師舉辦相關主題的專業講座，並由香港中文大學中醫學院副院長林志秀教授擔任嘉賓主持，吸引 200 多名本地業界人士參加。張博士在網上講座中重點解說以武漢和香港新冠患者為對象的舌苔研究，並分享他為本地病人提供遙距診治服務的經驗。 /

Chinese medicine practitioners believe that COVID-19 is associated with the stagnation of cold-dampness in the body. One of the tell-tale signs of dampness build-up within the body is a thick and greasy coating on the tongue. To educate the public on the concepts of dampness and tongue diagnosis in Chinese medicine and offer dietary tips for eliminating dampness, Dr. Zhang Shi-ping, Associate Professor of CMTR, delivered a webinar on 7 April, with gourmet columnist Mr. Stephen Ip Shue-kwan as the guest host.

In the webinar, Dr. Zhang introduced the standardised photographic protocol developed by his team for taking high-quality tongue images with smartphones, and a mobile application (i-heals.com) that they developed to analyse tongue images with artificial intelligence (AI) technology.

Dr. Zhang presented tongue images of COVID patients to illustrate the change in their tongue features from the onset of the disease to recovery. He also recommended a selection of soup recipes that are effective in expelling internal dampness for people with different types of body constitution and those who are at various stages of infection. The online event attracted around 200 live viewers and reached 1,000 views on YouTube in just a few days.

Prior to this webinar, Dr. Zhang organised a professional seminar exclusively for Chinese medicine practitioners, with Professor Lin Zhixiu, Associate Director of the School of Chinese Medicine at The Chinese University of Hong Kong, as the guest host. The online seminar, which was attended by over 200 local practitioners, focused on Dr Zhang's research findings on tongue coatings in COVID-19 patients in Wuhan and Hong Kong, as well as his experience in offering telemedicine services to local patients. /

## 呂愛平教授獲選歐洲科學院外籍院士

Professor Lyu Aiping elected Foreign Member of Academia Europaea



黃英豪博士中醫藥教授暨中醫藥學院院長呂愛平教授最近獲歐洲人文和自然科學院（歐洲科學院）選為外籍院士，以表揚他在系統醫學方面多年來的卓越學術成就。歐洲科學院成立於 1988 年，是一所在歐洲有廣泛代表性的科學、人文和文學學院，致力在人文、法律、經濟、社會及政治科學、數學、醫學、所有自然和技術科學等學術範疇力臻卓越。該學院的 4,500 多名院士均為頂尖的科學家 and 學者，當中包括 72 位諾貝爾獎得主。 /

Professor Lyu Aiping, Dr. Kennedy Y.H. Wong Endowed Professor in Chinese Medicine and Dean of Chinese Medicine, has recently been elected as a Foreign Member of the Academia Europaea in recognition of his sustained academic excellence in systems medicine. Founded in 1988, the Academia Europaea is the pan-European Academy of Sciences, Humanities and Letters. It is dedicated to the advancement and propagation of excellence in scholarship in the humanities; law; the economic, social, and political sciences; mathematics; medicine; and all branches of natural and technological sciences. The Academy hosts more than 4,500 members who are leading scientists and scholars, including 72 Nobel Prize laureates. /

## 鍾麗丹博士獲《中醫藥文化（英文）》選為優秀青年編委

Dr. Zhong Lidan named Outstanding Youth Editor by *Chinese Medicine and Culture*




教學科研部助理教授鍾麗丹博士於 2021 年擔任《中醫藥文化（英文）》編委，其卓越表現備受肯定。該雜誌是由上海市教育委員會支持、上海中醫藥大學和中華中醫藥學會出版的同行評審季刊，更是唯一以中醫藥人文領域為中心的學術期刊。鍾博士把自身在中醫和中西醫結合方面豐富的臨床和研究經驗帶到編輯部，並與國際頂尖學者團隊攜手合作，為讀者提供優質的編輯內容。 /

Dr. Zhong Lidan, Assistant Professor of CMTR, was recognised for the outstanding service she rendered on the editorial board of *Chinese Medicine and Culture* in 2021. The Journal is a peer-reviewed quarterly run by Shanghai University of Traditional Chinese Medicine and the China Association of Chinese Medicine under the aegis of the Shanghai Municipal Education Commission. It is the only academic journal devoted entirely to the humanistic aspect of Chinese medicine. Dr. Zhong brought her extensive clinical and research experience in Chinese medicine and integrative medicine to the board where she joined hands with an international team of elite scholars to deliver high quality editorial content to readers. /

## 學院科研成果在日內瓦國際發明展奪獎

SCM research projects clinch awards at  
Geneva International Exhibition of Inventions




學院研究人員的兩項科研成果在「2022 年日內瓦國際發明展」榮獲銀獎。其中一個得獎項目是由教學科研部主任張宏杰教授及其團隊研發的美白和抗衰老護膚產品系列。研究團隊發現中藥常用的石斛含有強效抗氧化和減少黑色素形成的特殊天然芪類化合物。團隊以此為基礎推出一系列廣受好評的護膚產品，並於內地、新加坡、馬來西亞、美國和台灣取得專利。另一獲獎項目是由教學科研部前研究助理教授曾少慧博士和博士後研究學人曾雅怡博士共同研發的植物營養素疤痕護理液。產品配方含有從蕨類植物中提取的小

分子黃烷醇糖苷，可抑制皮膚中被激活的肌成纖維細胞，改善隆起疤痕的外觀。有別於市場上眾多疤痕治療產品，此護理液不含矽膠，成分天然且無刺激性。這項發明已於香港、中國及美國取得專利。 /

Two research projects conducted by SCM researchers won silver medals at the Geneva International Exhibition of Inventions 2022. One of the winning projects is the development of a line of skin whitening and anti-ageing products by a research team led by Professor Zhang Hongjie, Director of CMTR. The team has discovered that the Dendrobium plants commonly used in Chinese medicine contain a specific class of natural compounds called stilbenoids which have a potent antioxidant and anti-melanogenic function. Based on their investigation, the team brought out the acclaimed skincare range which has been patented in the Mainland, Singapore, Malaysia, the US and Taiwan. The other winning project was the invention of a phytonutrient-based scar remedial fluid by Dr. Tsang Siu-wai, former Research Assistant Professor, and Dr. Tsang Nga-yi, Post-Doctoral Research Fellow from CMTR. The formula contains small molecules of flavanol glycosides extracted from ferns, which help improve the appearance of elevated scars by suppressing the activated myofibroblasts in the skin. This natural and non-irritating product is completely free of silicone, unlike a lot of the scar treatments on the market. Patents have been granted in Hong Kong, China and the US. /

## 許軍博士獲選為《JPA》青年編委

Dr. Xu Jun appointed Young Editor of *Journal of Pharmaceutical Analysis*



教學科研部研究助理教授許軍博士獲選為《*Journal of Pharmaceutical Analysis*》(JPA) 青年編委，任期兩年 (2022-2023)。在全球 95 名青年編委中，許博士是唯一來自香港的學者。《JPA》是經同行評審的藥物分析期刊。該期刊收錄於 SCIE、Scopus、PubMed 等多個數據庫。根據 2020 期刊引文報告，其影響因子為 4.769，在 275 本藥理學和藥學期刊中排行第 72 位。 /

Dr. Xu Jun, Research Assistant Professor of CMTR, has been appointed as Young Editor of *Journal of Pharmaceutical Analysis* for a two-year term (2022-2023). Among the 95 Young Editors selected from around the world, Dr. Xu is the only one from Hong Kong. *Journal of Pharmaceutical Analysis* is a peer-reviewed journal for all aspects of pharmaceutical analysis. The journal is indexed in databases including SCIE, Scopus, and PubMed with an impact factor of 4.769, ranking 72nd out of 275 journals in the category of Pharmacology & Pharmacy (JCR 2020). /



## 孫少文基金會捐贈港幣 2,500 萬元推動人工智能與中醫藥研究

Simon Suen Foundation contributes HK\$25 million towards AI and Chinese medicine research



孫少文基金會特意捐贈港幣 2,500 萬元支持浸大的人工智能與中醫藥臨床研究，尤其是有關運用可穿戴智能設施收集重要數據的研究項目。在去年 12 月 2 日舉行的支票致送儀式上，校長衛炳江教授由衷感謝基金會長期以來對浸大的支持，以及對傳承和弘揚中華傳統文化的承諾。他表示，大學在基金會的襄助下，定能在中醫藥教育、研究和服務方面精益求精，並加快智能化醫院的建設，提高中醫藥的臨床療效，而即將落成的中醫醫院更能在中醫藥發展中擔當「旗艦」及「轉化者」的角色，惠澤社群。 /

Simon Suen Foundation has donated HK\$25 million in support of HKBU's artificial intelligence and Chinese medicine clinical research, in particular the use of intelligent wearable devices to collect important data for related research projects. At the cheque presentation ceremony held on 2 December 2021, Professor Alexander Wai, President and Vice-Chancellor, expressed heartfelt thanks to the Foundation for its longstanding support for HKBU and its commitment to preserving and promoting traditional Chinese culture. He said that the generous donation will help the University promote excellence in Chinese medicine education, research and services. In addition, it will foster the development of a smart hospital and enhance the efficacy of Chinese medicine treatments, with the forthcoming Chinese medicine hospital playing the role of the 'flagship' and 'change driver' of Chinese medicine development for the benefit of the community. /

## 學院獲香港熊貓教育基金會捐贈港幣 400 萬元支持乳癌研究

SCM receives HK\$4 million in donation for breast cancer research from  
Hong Kong Panda Education Foundation



浸大獲香港熊貓教育基金會慷慨捐贈港幣 400 萬元，以支持學院的乳癌研究工作。為鳴謝基金會的捐助，大學在 1 月 17 日舉行支票致送儀式。基金會創會主席閻小穎先生在活動上讚揚大學銳意推動中醫藥發展。他表示：「浸大是本地中醫藥教育的先驅，致力從事高端研究，並在提供中醫藥臨床服務方面具備豐富經驗。香港特區政府早前向浸大批出服務契約，委託營運香港首間中醫醫院，足證浸大在香港中醫藥發展的領導地位。」 /

HKBU has received a generous donation of HK\$4 million from the Hong Kong Panda Education Foundation in support of SCM's research on breast cancer. In appreciation of the Foundation's beneficence, the University held a cheque presentation ceremony on 17 January. Mr. Simon Yim, Founding Chairman of the Foundation, acknowledged the University's dedication to the advancement of Chinese medicine at the ceremony. He said: "HKBU is the pioneer of Chinese medicine education in Hong Kong. It is also devoted to cutting-edge research, and it has rich experience in providing Chinese medicine clinical services. The HKSAR Government's recent selection of HKBU as the contractor for the service deed of Hong Kong's first Chinese medicine hospital is a testament to its leading role in Hong Kong's development of Chinese medicine." /

## 陳漢賢伉儷慈善信託基金捐贈港幣 1,500 萬元資助學院臨床研究

### Chan Hon Yin Couple Charity Trust donates HK\$15 million to fund SCM's clinical research

陳漢賢伉儷慈善信託基金慷慨捐贈港幣 1,500 萬元，以助學院拓展臨床研究工作。在去年 12 月 6 日舉行的支票致送儀式上，衛炳江教授衷心感謝基金及陳氏家族三代在過去 20 多年一直鼎力支持學院的發展。2000 年，基金捐贈港幣 900 萬元，以助大學創辦香港首個中藥學學士（榮譽）學位課程。為表謝意，學院大樓的中醫診所於 2001 年正式命名為香港浸會大學陳漢賢伉儷中醫專科診所暨臨床規範研究中心。基金其後繼續斥資力行，襄助學院多個研究項目，並設立陳漢賢紀念中醫獎學金和胡雪芳中醫臨床研究深造基金。/



The Chan Hon Yin Couple Charity Trust has made a generous donation of HK\$15 million to support SCM's clinical research. At the cheque presentation ceremony held on 6 December 2021, Professor Alexander Wai expressed his heartfelt gratitude to the Trust and the three generations of the Chan family for their unwavering support for SCM for more than two decades. In 2000, the Trust donated HK\$9 million to the University to launch Hong Kong's first-ever Bachelor of Pharmacy (Hons) in Chinese Medicine programme. In appreciation of the Trust's generosity, the Chinese medicine clinic in the SCM building was named the HKBU Mr. & Mrs. Chan Hon Yin Chinese Medicine Specialty Clinic and Good Clinical Practice Centre in 2001. Since then, the Trust has continued to show support for SCM by funding a number of its research initiatives, the Chan Hon Yin Memorial Scholarship on Chinese Medicine and the Wu Suet Fong Chinese Medicine Clinical Fellowship. /

## 卞兆祥教授分享中醫藥發展見解

### Professor Bian Zhaoxiang shares insights on the development of Chinese medicine

臨床部主任卞兆祥教授於 1 月 26 日為「浸大傑出學人講座系列 2022」主講首場講座，題為「中醫藥傳統智慧及其應用：機遇與挑戰」。講座由浸大創意研究院及研發辦公室合辦，吸引 140 多名師生和校友參與。卞教授在講座上表示，大學期望透過籌備及營運香港首間中醫醫院，滿足公眾對優質中醫藥服務的迫切需求。他相信，不同學科需要積極展開更多對話和研究合作，方能充分發揮傳統中醫藥的優勢，造福社會，尤其是解決人口老化等持續湧現的挑戰。/



Professor Bian Zhaoxiang, Director of CLNC, delivered a lecture titled "Traditional Wisdom of Chinese Medicine and its Application: Opportunity and Challenges" on 26 January. It was the first talk of the HKBU Distinguished Lecture Series 2022 co-organised by the Institute of Creativity and the Research Office at HKBU. The event drew more than 140 participants including teachers, students and alumni. In the lecture, Professor Bian said that the University aspires to meet the pressing demand for quality Chinese medicine services through the preparation and operation of Hong Kong's first Chinese medicine hospital. He also said he believes that more constructive dialogues and research collaboration among various disciplines are required in order to make full use of traditional Chinese medicine to benefit society, especially in terms of addressing ongoing challenges such as ageing population. /



## 學院首次參與亞洲急診醫學會議

SCM participates in ACEM for the first time

副院長（教與學）李敏教授於去年 12 月 17 日率領學院代表團，以協辦機構的身分出席第十一屆亞洲急診醫學會議開幕儀式，而是次雙年國際會議更首度加入中醫元素。在為期三天的會議中，李教授除了親身主持「急診中的中西醫結合」環節，更在會議前聯同教學科研部講師蔡嘉傑博士舉辦「中醫藥概論」工作坊，內容涵蓋中醫的一般理論和基本技能，如四診、針灸、推拿、正骨和藥材使用。 /



Professor Li Min, Associate Dean (Teaching and Learning) of Chinese Medicine, led a SCM delegation to attend the opening ceremony of the 11<sup>th</sup> Asian Conference on Emergency Medicine (ACEM) on 17 December 2021. It was the first time for this biannual international conference to incorporate a Chinese medicine component, and SCM was one of the supporting institutions. In addition to chairing a session titled "Integration of Traditional Chinese and Western Medicine in Emergency Medicine" during the three-day conference, Professor Li also organised a pre-conference workshop on "Introduction of Chinese Medicine" with Dr. Tony Chua, Lecturer of CMTR. The workshop covered general concepts and basic skills of Chinese medicine, such as four examinations, acupuncture, *tui na*, bone-setting and the use of medicinal herbs. /

## 陳虎彪教授為本地中學提供專業意見

Professor Chen Hubiao lends expertise to local secondary school



教學科研部陳虎彪教授和余堅文博士於 1 月 8 日到訪天主教母佑會蕭明中學，視察該校預留建設中藥園的土地。陳教授運用他在藥用植物學方面的豐富知識，為中藥園選址、植物品種選擇和栽培方式提供專業意見。余博士亦藉此機會與學校管理層商討學院為年輕學生提供基礎課程的構思，冀讓同學盡早接觸中醫藥。 /

Professor Chen Hubiao and Dr. Kevin Yue from CMTR visited DHMC Siu Ming Catholic Secondary School on 8 January to inspect a site reserved by the school for the construction of an herbal garden. Professor Chan lent his expertise in medicinal botany to the project by offering expert advice on the location of the herbal

garden, selection of plant species and cultivation methods. Dr. Yue also took the opportunity to discuss with the school management the possibility of giving the young students a head start learning about Chinese medicine by offering elementary courses to them. /



## 學生與病人攜手推廣保健養生方式

Students join hands with patients to promote health maintenance strategies



本學年（2021/22）的骨傷課程為中醫本科學生帶來獨特的服務學習體驗，透過與科創社工學會、香港小腦萎縮症協會、新健社和其他非政府組織合作，夥拍病人一同推廣健康生活。自疫情爆發以來，不少患者無法如常外出就醫或前往支援組織，這對長期病患人士影響尤深。為協助患者在家保持健康體魄，服務團隊特別製作一系列的影片，介紹八段錦、穴位推拿、食療等各種健康管理方式。相關影片將上載至各個合作機構的網站。 /

In partnership with the Society of Innovative Social Work, Hong Kong Spinocerebellar Ataxia Association, Hong Kong Stroke Association and other non-governmental organisations, the Orthopaedic and Traumatology course for this academic year (2021/22) provided BCM students with a unique service-learning experience in which they teamed up with patients to

promote wellness. The coronavirus outbreak has prevented a lot of patients, especially those with chronic illnesses, from leaving their homes and getting access to medical care and their support groups. In order to help these people maintain health and fitness at home, the service team has produced a series of videos introducing various health management approaches, such as *Baduanjin*, acupoint *tui na* and food therapy. These videos will be available on the websites of the partnering organisations. /

## 持續及專業教育部舉辦修課式碩士課程簡介會

DCPE organises information session on taught postgraduate programmes

學院開辦的修課式碩士學位課程一直深受矢志於醫護界發展或更上一層樓的人士青睞。為協助有意報讀的人士按個人需要選擇最合適的課程，持續及專業教育部於 1 月 22 日舉辦線上簡介會，部門教師在會上闡述各個課程的學習目標、結構、內容和入學要求，並逐一解答參加者的查詢。 /

The taught postgraduate programmes offered by SCM have remained popular amongst those who aspire to carve out a career or achieve the next level of success in the health industry. To help its prospective students choose a programme that is most suited to their needs, the Division of Continuing and Professional Education (DCPE) hosted an online information session on 22 January. Staff of the Division gave an informative presentation about the learning objectives, structure, content and entrance requirements of each programme and answered the participants' inquiries in great detail. /

## 學院為中學生提供職業講座

SCM delivers career talk for secondary school students

學院自 2016 年一直支持由天水圍官立中學舉辦的職業博覽會。上年度的活動於 11 月 12 日舉行，教學科研部技術導師文昊賢先生應邀主持職業講座，詳細介紹學院畢業生的就業前景，以及業界未來的機遇和挑戰。是次講座和整個博覽會的宗旨在於協助學生按照自己的職業抱負確立學習路向。 /

SCM has been showing support for the Career Expo organised by TSW Government Secondary School since 2016. At the annual event held on 12 November, Mr. Steven Man, Technical Instructor of CMTR delivered a career talk in which he went into detail about the career prospects of SCM students and the opportunities and challenges facing the industry. The purpose of the talk and the event as a whole was to help young students identify their study paths based on their occupational aspirations. /

## CMCF 與支持者聯手向長者和前線醫護人員送上防疫物資

CMCF and supporters pitch in to provide anti-epidemic supplies for elderly and frontline healthcare workers



國際獅子總會中國港澳三〇三區及其兩個屬會（九龍城獅子會和米埔獅子會）向獅子會與香港浸會大學中醫藥慈善基金（CMCF）捐贈大批防疫物資，當中包括快速測試劑、KN95 口罩和中成藥，並經學院營運的 10 間中醫藥診所派發予 60 歲或以上的年長病人。此外，CMCF 捐獻港幣 138,000 元，贊助保良局（安老服務）購置防護裝備和快速測試劑，以供轄下 16 間安老院舍和日間護理中心的前線員工使用。臨床部亦出一分力，捐出共 6,000 份浸大防感方中藥予保良局的前線人員，同時透過屯門獅子會轉派物資予屯門和元朗區的長者和弱勢社群。 /

Lions Clubs International District 303 – Hong Kong & Macao, China and two of its branches, namely Lions Club of Kowloon City and Lions Club of Hong Kong Mai Po, have come together to donate a batch of rapid antigen test (RAT) kits, KN95 masks and proprietary Chinese medicines to Lions and HKBU Chinese Medicine Charity Foundation (CMCF). The anti-epidemic supplies will be distributed to the elderly patients aged 60 or above visiting the 10 Chinese medicine clinics operated by SCM. On the other hand, CMCF has donated HK\$138,000 to Po Leung Kuk (Elderly Service) for the procurement of protective equipment and RAT kits for the frontline staff of its 16 elderly homes and day care centres. CLNC joined in the charitable efforts by gifting a total of 6,000 doses of the HKBU Chinese Medicine Immunity Enhancement Remedy to the frontline staff of Po Leung Kuk as well as the elderly and underprivileged living in Tuen Mun and Yuen Long through Lions Club of Tuen Mun. /

## 學院於浸大中醫日贈醫施藥

SCM offers free Chinese medicine services to the public on annual Community Day



臨床部延續傳統，於 5 月 1 日在八間浸大中醫診所舉辦浸大中醫日。一如以往，成功登記的市民可接受免費健康諮詢和治療，並獲贈三劑中藥。今年，部門更特別安排疫症康復者優先享用服務，以助他們應對新冠後遺症。 /

In keeping with its tradition, CLNC started off the month of May by hosting the HKBU Chinese Medicine Community Day at eight of the HKBU Chinese medicine clinics. As usual, health consultations and treatments inclusive of three doses of Chinese medicines per person were offered for free to those who had successfully registered. Priority for the service was given to recovered COVID-19 patients this year to help them manage the aftereffects of infection. /



## 臨床部增設《浸大中醫在線》全新內容及特別環節 CLNC adds new content and features to “HKBU Chinese Medicine On-Air”

臨床部製作的中醫訪談節目《浸大中醫在線》自2020年首播以來，一直廣受好評。節目於去年10月推出第四季，並引入不少新元素，包括由學院醫師解答患者常見問題的環節。為拓展觀眾層面，昔日的節目內容新增英文字幕，並陸續上載至「擁抱健康」YouTube頻道。/

The medical talk show “HKBU Chinese Medicine On-Air” produced by CLNC has continued to garner praise from viewers since its debut in 2020. It returned last October with the fourth season introducing new elements such as a Q&A session in which SCM’s medical experts answer some of the most commonly asked questions from patients. In order to reach a wider audience, the early seasons have been re-released with English subtitles on the Embrace Health YouTube channel, and the rest is currently in the works. /



## 學院拍攝健身操短片推廣抗疫健康生活

SCM creates exercise tutorials to promote health during pandemic



**3. 聽宮**  
位於耳屏前，張口時呈凹陷  
張開嘴巴，用雙手食指揉按



疫情期間，學院致力支援廣大市民維持健康生活。香港浸會大學一賽馬會中醫疾病預防與健康管理中心於2月特意在「擁抱健康」YouTube頻道上載兩段全新「穴位經絡操」影片。此健身操把穴位和經絡的按壓與現代舞蹈動作相互融合，以達至強身健體的效果。伴隨影片中輕快的音樂舞動身體，更可舒緩情緒。/

SCM has set itself on a mission to support the public in maintaining good health during

the pandemic. In February, the HKBU – Jockey Club Chinese Medicine Disease Prevention and Health Management Centre released two new videos on the Embrace Health YouTube channel introducing an exercise routine that combines the benefits of acupoint and meridian stimulation and modern dance movements to achieve health strengthening effects. It is uplifting to both the body and mind to perform the routine while listening to the upbeat music of the videos. /




## 阮俊森同學獲頒 龍的文化醫學博士生獎學金

### Sam Yuen wins Dragon Culture Doctoral Scholarships for Medicine

博士研究生阮俊森奪得龍的文化醫學博士生獎學金，獲資助港幣 50,000 元，用以研究帕金森症中西藥結合治療。該獎學金於 2021 年由龍的文化慈善基金設立，旨在支持博士生開展中西醫藥學領域的研究工作。阮同學將以流行病學為基礎，探討中醫治療帕金森症的方案及療效，並會採用臨床研究方法分析中醫治療帕金森症的安全性及有效性。是項研究乃首個以中西醫臨床指南指導用藥的臨床試驗。PhD student Sam Yuen has been

awarded a scholarship of HK\$50,000 under the Dragon Culture

Doctoral Scholarships for Medicine in support of his research on the use of integrated medicine in the treatment of Parkinson's disease (PD). The Scholarships were launched by Dragon Culture Charity Fund Limited in 2021 to support the research endeavours of doctoral students in the fields of Chinese and Western medicine. Sam will take an epidemiological approach to examining the Chinese medicine therapeutic strategies for PD and their efficacy. He will evaluate the safety and effectiveness of Chinese medicine treatments for PD by means of clinical studies. His proposed research will be the first clinical trial ever conducted for PD medication under the guidelines on clinical practice of integrated medicine. /



## 中醫本科生實習 表現備受讚揚

### BCM students commended for outstanding performance during internship



廣東省中醫院近日向學院致函，表揚中醫本科六年級生在專科研習過程中表現超卓。信中特別讚揚陳葦彥（左一）、王均宥（左二）和楊智名（右）同學具備紮實中醫基礎，為人謙遜有禮，力學篤行。此專科研習屬為期三個月的深造課程，期間學生會在所選領域接受資深中醫師的高階臨床培訓。

The School has recently received a letter of commendation from Guangdong Provincial Hospital of Traditional Chinese Medicine in regard to the exceptional performance of the BCM Year 6 students during their specialty training at the hospital. In particular, students

Jeremy Chan (first left), Wong Kwan Yau (2<sup>nd</sup> left) and Yang Zhiming (right) were complimented on their solid knowledge of Chinese medicine, diligence, integrity, modesty and courtesy. The specialty training is an intensive three-month course during which students receive advanced clinical training in an area of interest from veteran Chinese medicine practitioners. /



## 龐嶷醫師 Mr. Pang Yi

臨床部中醫臨床副教授 Associate Professor of Practice, Clinical Division

龐醫師先後於廣州中醫藥大學取得中醫學士和碩士學位，來港前曾任廣東省中醫院副主任中醫師及廣州中醫藥大學第二臨床醫學院中醫內科碩士研究生導師。他自2011年擔任仁濟醫院—香港浸會大學中醫教研中心高級中醫師（西九龍），至今年4月獲委任為臨床部中醫臨床副教授。龐醫師的主要專業研究範圍包括中醫藥治療泌尿系統和內科疾病。Mr. Pang graduated from Guangzhou University of Chinese Medicine (GZUCM) with bachelor's and master's degrees in Chinese medicine. Before coming to Hong Kong, he served as Deputy Director of Guangdong Provincial Hospital of Traditional Chinese Medicine and tutor of postgraduate students of Chinese internal medicine at Second Clinical Medical College of GZUCM. He was Senior Chinese Medicine Practitioner at Yan Chai Hospital - HKBU Clinical Centre for Training and Research in Chinese Medicine (West Kowloon) since 2011, before being appointed as Associate Professor of Practice of CLNC in April 2022. His research focuses on the traditional Chinese medicine approach to the treatment of urological and internal medicine diseases.



## 伏勇博士 Dr. Fu Yong

臨床部中醫臨床助理教授 Assistant Professor of Practice, Clinical Division

伏博士於山東中醫藥大學取得中醫學學士學位，後於福建中醫藥大學取得中醫骨傷科學碩士和博士學位。他來港前擔任福建中醫藥大學副教授和主治中醫師，負責臨床門診、教學等工作長達10年，至2022年3月獲學院委任為臨床部中醫臨床助理教授。其專業研究範圍涵蓋推拿手法和針灸治療頸肩腰腿痛等疾病。Dr. Fu graduated from Shandong University of Traditional Chinese Medicine with a bachelor's degree in medicine. He went on to obtain master's and Ph.D. degrees in orthopaedic science from Fujian University of Traditional Chinese Medicine (FJUTCM). Before coming to Hong Kong, he worked as Associate Professor and Chinese Medicine Practitioner at FJUTCM, where he provided clinical outpatient services and performed teaching and other duties for a decade. In March 2022, he was appointed by SCM as Assistant Professor of Practice of CLNC. His research interests include the treatment of neck, shoulder, waist and leg pain and other diseases with *tui na* and acupuncture.



## 余嘉玲醫師 Ms. Yu Ka-ling

臨床部中醫臨床助理教授 Assistant Professor of Practice, Clinical Division

余醫師於浸大先後取得中醫學學士及生物醫學理學士（榮譽）雙學位和中醫碩士學位（針灸）。她於2007年至2022年任職仁濟醫院暨香港浸會大學中醫教研中心（葵青），從事臨床、教學及科研工作，並兩度獲得香港醫院管理局獎學金，派往中國中醫科學院西苑醫院及廣東省中醫院接受中醫腫瘤專科培訓。她的專業研究方向為中醫藥及針灸防治惡性腫瘤。Ms. Yu obtained her Bachelor of Chinese Medicine and Bachelor of Science (Hons.) in Biomedical Science double degree and master's degree in acupuncture from HKBU. Between 2007 and 2022, she worked at Yan Chai Hospital cum HKBU Chinese Medicine Clinic cum Training and Research Centre (Kwai Tsing), where she undertook clinical, teaching and research work. She was awarded two scholarships by Hong Kong Hospital Authority to pursue oncology specialty training at Xi Yuan Hospital of China Academy of Chinese Medical Sciences and Guangdong Provincial Hospital of Traditional Chinese Medicine. Her research focuses on the application of traditional Chinese medicine and acupuncture in the prevention and treatment of malignant tumors.

聯絡我們  
Contact Us

## 香港浸會大學中醫藥學院

九龍塘浸會大學道七號賽馬會中醫藥學院大樓

### School of Chinese Medicine, Hong Kong Baptist University

Jockey Club School of Chinese Medicine Building,  
7 Baptist University Road, Kowloon Tong, Kowloon.

#### 院長辦公室 Dean's Office

##### 四樓 4/F

電話 Tel (852) 3411 2457  
傳真 Fax (852) 3411 2917  
電郵 Email [scmd@hkbu.edu.hk](mailto:scmd@hkbu.edu.hk)  
網址 Website <http://scm.hkbu.edu.hk>

#### 教學科研部 Teaching and Research Division

##### 四樓 4/F

電話 Tel (852) 3411 2481  
傳真 Fax (852) 3411 2461  
電郵 Email [cmtr@hkbu.edu.hk](mailto:cmtr@hkbu.edu.hk)  
網址 Website <http://scm.hkbu.edu.hk/academicprogrammes>

#### 技術開發部 Technology Development Division

##### 四樓 4/F

電話 Tel (852) 3411 2945  
傳真 Fax (852) 3411 2902  
電郵 Email [scmtdd@hkbu.edu.hk](mailto:scmtdd@hkbu.edu.hk)  
網址 Website <http://scm.hkbu.edu.hk/tdd>

#### 臨床部 Clinical Division

##### 三樓 3/F

電話 Tel (852) 3411 2968 / (852) 3411 2988  
傳真 Fax (852) 3411 2929  
電郵 Email [scmcld@hkbu.edu.hk](mailto:scmcld@hkbu.edu.hk)  
網址 Website <http://scm.hkbu.edu.hk/cmclinic>

#### 持續及專業教育部 Division of Continuing & Professional Education

##### 四樓417室 Rm417, 4/F

電話 Tel (852) 3411 2912 / (852) 3411 5748  
傳真 Fax (852) 3411 2918  
電郵 Email [dcpe@hkbu.edu.hk](mailto:dcpe@hkbu.edu.hk)  
網址 Website <http://scm.hkbu.edu.hk/dcpe>

#### 秘書處 Secretariat

##### 四樓 4/F

電話 Tel (852) 3411 5387  
傳真 Fax (852) 3411 2902  
電郵 Email [scm@hkbu.edu.hk](mailto:scm@hkbu.edu.hk)  
網址 Website <http://scm.hkbu.edu.hk>